Stockhead’s Prepped and Primed video series is a yearly wrap up address from company leaders showcasing latest achievements, discoveries and developments of emerging ASX companies. 

In this instalment Steven Yatomi-Clarke, CEO and managing director at Prescient Therapeutics (ASX:PTX) shares his outlook for 2023.

Prescient Therapeutics develop a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. The company has licensed technologies from and in collaboration with world-leading cancer centres in the US and Australia.

To hear about the company’s upcoming 2023, click above.

Read MoreHealth

Featured Companies

You might be interested in